INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 155 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $99,557,247 | -14.4% | 1,911,022 | +4.0% | 0.01% | -14.3% |
| Q2 2023 | $116,303,494 | +22.8% | 1,836,757 | +5.0% | 0.01% | +16.7% |
| Q1 2023 | $94,709,362 | +106974.3% | 1,749,018 | +4.6% | 0.01% | 0.0% |
| Q4 2022 | $88,452 | -99.9% | 1,671,437 | +3.3% | 0.01% | +9.1% |
| Q3 2022 | $75,299,000 | -16.9% | 1,618,310 | +1.9% | 0.01% | -15.4% |
| Q2 2022 | $90,665,000 | +0.7% | 1,588,399 | +8.0% | 0.01% | +18.2% |
| Q1 2022 | $90,007,000 | +33.7% | 1,470,957 | +14.4% | 0.01% | +37.5% |
| Q4 2021 | $67,299,000 | +41.8% | 1,285,814 | +1.0% | 0.01% | +33.3% |
| Q3 2021 | $47,447,000 | -7.2% | 1,272,720 | +1.6% | 0.01% | -14.3% |
| Q2 2021 | $51,155,000 | +26.2% | 1,253,202 | +4.9% | 0.01% | +16.7% |
| Q1 2021 | $40,537,000 | +15.1% | 1,194,753 | +7.8% | 0.01% | 0.0% |
| Q4 2020 | $35,234,000 | +36.9% | 1,107,996 | +10.4% | 0.01% | +20.0% |
| Q3 2020 | $25,746,000 | +19.0% | 1,003,364 | +19.0% | 0.01% | 0.0% |
| Q2 2020 | $21,640,000 | +74.6% | 843,024 | +4.5% | 0.01% | +66.7% |
| Q1 2020 | $12,397,000 | -71.7% | 806,602 | -36.9% | 0.00% | -40.0% |
| Q4 2019 | $43,882,000 | +800.5% | 1,278,996 | +96.1% | 0.01% | +400.0% |
| Q3 2019 | $4,873,000 | -41.7% | 652,371 | +1.2% | 0.00% | -50.0% |
| Q2 2019 | $8,364,000 | +12.1% | 644,414 | +5.2% | 0.00% | 0.0% |
| Q1 2019 | $7,461,000 | -37.5% | 612,614 | -41.6% | 0.00% | 0.0% |
| Q4 2018 | $11,946,000 | +10.4% | 1,048,922 | +110.3% | 0.00% | -33.3% |
| Q3 2018 | $10,825,000 | +30.6% | 498,873 | +6.3% | 0.00% | 0.0% |
| Q2 2018 | $8,289,000 | -5.6% | 469,119 | +12.4% | 0.00% | 0.0% |
| Q1 2018 | $8,783,000 | +51.2% | 417,256 | +4.0% | 0.00% | +50.0% |
| Q4 2017 | $5,809,000 | +9.2% | 401,194 | +19.0% | 0.00% | 0.0% |
| Q3 2017 | $5,320,000 | +49.5% | 337,189 | +17.7% | 0.00% | +100.0% |
| Q2 2017 | $3,558,000 | -19.1% | 286,530 | +5.8% | 0.00% | -50.0% |
| Q1 2017 | $4,400,000 | +11.0% | 270,782 | +3.1% | 0.00% | 0.0% |
| Q4 2016 | $3,965,000 | +5.3% | 262,759 | +6.4% | 0.00% | 0.0% |
| Q3 2016 | $3,764,000 | -56.1% | 246,992 | +11.9% | 0.00% | -60.0% |
| Q2 2016 | $8,571,000 | +50.4% | 220,799 | +7.7% | 0.01% | +66.7% |
| Q1 2016 | $5,697,000 | -45.3% | 204,936 | +5.8% | 0.00% | -50.0% |
| Q4 2015 | $10,415,000 | +54.5% | 193,635 | +15.0% | 0.01% | +50.0% |
| Q3 2015 | $6,739,000 | +27.9% | 168,323 | +2.0% | 0.00% | +33.3% |
| Q2 2015 | $5,271,000 | +40.9% | 164,990 | +5.3% | 0.00% | +50.0% |
| Q1 2015 | $3,741,000 | +84.7% | 156,661 | +36.5% | 0.00% | +100.0% |
| Q4 2014 | $2,025,000 | +32.2% | 114,734 | +2.7% | 0.00% | 0.0% |
| Q3 2014 | $1,532,000 | +19.3% | 111,756 | +46.6% | 0.00% | 0.0% |
| Q2 2014 | $1,284,000 | +26.8% | 76,206 | +36.6% | 0.00% | 0.0% |
| Q1 2014 | $1,013,000 | – | 55,775 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |